Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis

References

• Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937-51; https://doi.org/10.1182/blood-2009-03-209262
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005; 11:546-54; https://doi.org/10.1016/j.molmed.2005.10.003
   PubMed Web of Science ®Google Scholar
• Lavi N. Calreticulin mutations in myeloproliferative neoplasms. Rambam Maimonides Med J 2014; 5:e0035; PMID:25386351; https://doi.org/10.5041/RMMJ.10169
   PubMedGoogle Scholar
• Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, Bass AJ, Pretz J, Ahn J, Hricik T, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014; 123:e123-33; PMID:24740812; https://doi.org/10.1182/blood-2014-02-554634
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, Guglielmelli P, Pungolino E, Caramella M, Maffioli M, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115:1703-8; PMID:20008785; https://doi.org/10.1182/blood-2009-09-245837
   PubMed Web of Science ®Google Scholar
• Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L, et al. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. Am J Hematol 2016; 92:37-41; PMID:27701770; https://doi.org/10.1002/ajh.24572
   PubMed Web of Science ®Google Scholar
• Campanelli R, Rosti V, Fois G, Bonetti E, Barosi G, Massa M. CD14(bright)CD16(low) intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis. Exp Hematol 2014; 42:244-6; PMID:24333662; https://doi.org/10.1016/j.exphem.2013.12.002
   PubMed Web of Science ®Google Scholar
• Satpathy AT, Wu X, Albring JC, Murphy KM. Re(de)fining the dendritic cell lineage. Nat Immunol 2012; 13:1145-54; PMID:23160217; https://doi.org/10.1038/ni.2467
   PubMed Web of Science ®Google Scholar
• Keohane C, Kordasti S, Seidl T, Perez Abellan P, Thomas NS, Harrison CN, McLornan DP, Mufti GJ. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol 2015; 171:60-73; PMID:26075866; https://doi.org/10.1111/bjh.13519
   PubMed Web of Science ®Google Scholar
• Massa M, Campanelli R, Fois G, Villani L, Bonetti E, Catarsi P, Poletto V, Viarengo G, De Amici M, Rosti V, et al. Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis. Blood 2016; 128:1660-2; PMID:27531678; https://doi.org/10.1182/blood-2016-03-704577
   PubMed Web of Science ®Google Scholar
• Wang JC, Sindhu H, Chen C, Kundra A, Kafeel MI, Wong C, Lichter S. Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα. PLoS One 2015; 10:e0116723; PMID:25793623; https://doi.org/10.1371/journal.pone.0116723
   PubMed Web of Science ®Google Scholar
• Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM. Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α. Blood 2011; 118:2170-3; PMID:21708889; https://doi.org/10.1182/blood-2011-03-340992
   PubMed Web of Science ®Google Scholar
• Froom P, Aghai E, Kinarty A, Lahat N. Decreased natural killer (NK) activity in patients with myeloproliferative disorders. Cancer 1989; 64:1038-40; PMID:2788028; https://doi.org/10.1002/1097-0142(19890901)64:5%3c1038::AID-CNCR2820640513%3e3.0.CO;2-W
   PubMed Web of Science ®Google Scholar
• Briard D, Brouty-Boyé D, Giron-Michel J, Azzarone B, Jasmin C, Le Bousse-Kerdilès C. Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis. Clin Immunol 2003; 106:201-12; PMID:12706407; https://doi.org/10.1016/S1521-6616(02)00046-3
   PubMed Web of Science ®Google Scholar
• Sonnenberg GF, Artis D. Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat Med 2015; 21:698-708; PMID:26121198; https://doi.org/10.1038/nm.3892
   PubMed Web of Science ®Google Scholar
• Hazenberg MD, Spits H. Human innate lymphoid cells. Blood 2014; 124:700-9; PMID:24778151; https://doi.org/10.1182/blood-2013-11-427781
   PubMed Web of Science ®Google Scholar
• Artis D, Spits H. The biology of innate lymphoid cells. Nature 2015; 517:293-301; PMID:25592534; https://doi.org/10.1038/nature14189
   PubMed Web of Science ®Google Scholar
• Trabanelli S, Curti A, Lecciso M, Salomé B, Riether C, Ochsenbein A, Romero P, Jandus C. CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis. Haematologica 2015; 100:e257-60; PMID:25710455; https://doi.org/10.3324/haematol.2014.119602
   PubMed Web of Science ®Google Scholar
• Munneke JM, Björklund AT, Mjösberg JM, Garming-Legert K, Bernink JH, Blom B, Huisman C, van Oers MH, Spits H, Malmberg KJ, et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood 2014; 124:812-21; PMID:24855210; https://doi.org/10.1182/blood-2013-11-536888
   PubMed Web of Science ®Google Scholar
• Shuai K, Liu B. Regulation of JAK–STAT signalling in the immune system. Nat Rev Immunol 2003; 3:900-11; PMID:14668806; https://doi.org/10.1038/nri1226
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29:1356-63; PMID:21300928; https://doi.org/10.1200/JCO.2010.32.9490
   PubMed Web of Science ®Google Scholar
• Mondet J, Hussein K, Mossuz P. Circulating cytokine levels as markers of inflammation in philadelphia negative myeloproliferative neoplasms: Diagnostic and prognostic interest. Mediators Inflamm 2015; 2015:670580; PMID:26525644; https://doi.org/10.1155/2015/670580
   PubMed Web of Science ®Google Scholar
• Brodie T, Brenna E, Sallusto F. OMIP-018: chemokine receptor expression on human T helper cells. Cytometry A 2013; 83:530-2; PMID:23504907; https://doi.org/10.1002/cyto.a.22278
   PubMed Web of Science ®Google Scholar
• Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood 2013; 121:2402-14; PMID:23325835; https://doi.org/10.1182/blood-2012-09-378653
   PubMed Web of Science ®Google Scholar
• Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev 2013; 252:116-32; PMID:23405899; https://doi.org/10.1111/imr.12027
   PubMed Web of Science ®Google Scholar
• Boniface K, Blumenschein WM, Brovont-Porth K, McGeachy MJ, Basham B, Desai B, Pierce R, McClanahan TK, Sadekova S, de Waal Malefyt R. Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage. J Immunol 2010; 185:679-87; PMID:20511558; https://doi.org/10.4049/jimmunol.1000366
   PubMed Web of Science ®Google Scholar
• Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30:899-911; PMID:19464196; https://doi.org/10.1016/j.immuni.2009.03.019
   PubMed Web of Science ®Google Scholar
• Porcellini S, Traggiai E, Schenk U, Ferrera D, Matteoli M, Lanzavecchia A, Michalak M, Grassi F. Regulation of peripheral T cell activation by calreticulin. J Exp Med 2006; 203:461-71; PMID:16492806; https://doi.org/10.1084/jem.20051519
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leukemia Res 2013; 37:214-20; https://doi.org/10.1016/j.leukres.2012.10.020
   PubMed Web of Science ®Google Scholar
• Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. THE IL-4 RECEPTOR: Signaling Mechanisms and Biologic Functions. Annu Rev Immunol 1999; 17:701-38; PMID:10358772; https://doi.org/10.1146/annurev.immunol.17.1.701
   PubMed Web of Science ®Google Scholar
• van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 2012; 119:3383-93; PMID:22323450; https://doi.org/10.1182/blood-2011-11-370130
   PubMed Web of Science ®Google Scholar
• Lacey DC, Achuthan A, Fleetwood AJ, Dinh H, Roiniotis J, Scholz GM, Chang MW, Beckman SK, Cook AD, Hamilton JA. Defining GM-CSF– and Macrophage-CSF–Dependent macrophage responses by In Vitro models. J Immunol 2012; 188:5752-65; PMID:22547697; https://doi.org/10.4049/jimmunol.1103426
   PubMed Web of Science ®Google Scholar
• Wang JC, Kundra A, Andrei M, Baptiste S, Chen C, Wong C, Sindhu H. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm. Leuk Res 2016; 43:39-43; PMID:26943702; https://doi.org/10.1016/j.leukres.2016.02.004
   PubMed Web of Science ®Google Scholar
• Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013; 122:4047-53; PMID:24174625; https://doi.org/10.1182/blood-2013-02-485888
   PubMed Web of Science ®Google Scholar
• Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P. The JAK-inhibitor Ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013;122: 1192-202; PMID:23770777; https://doi.org/10.1182/blood-2013-03-484642
   PubMed Web of Science ®Google Scholar
• Ma DY, Clark EA. The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol 2009; 21:265-72; PMID:19524453; https://doi.org/10.1016/j.smim.2009.05.010
   PubMed Web of Science ®Google Scholar
• Magee CN, Boenisch O, Najafian N. The role of costimulatory molecules in directing the functional differentiation of alloreactive T helper cells. Am J Transplant 2012; 12:2588-600; PMID:22759274; https://doi.org/10.1111/j.1600-6143.2012.04180.x
   PubMed Web of Science ®Google Scholar
• Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007; 136:745-51; PMID:17313377; https://doi.org/10.1111/j.1365-2141.2007.06497.x
   PubMed Web of Science ®Google Scholar
• Bogani C, Guglielmelli P, Antonioli E, Pancrazzi A, Bosi A, Vannucchi AM. B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica 2007; 92:258-9; PMID:17296581; https://doi.org/10.3324/haematol.10527
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Tonetti C, Massé A, Godin I, Le Couedic JP, Debili N, Saulnier P, Casadevall N, Vainchenker W, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2007; 109:71-7; PMID:16954506; https://doi.org/10.1182/blood-2006-03-007146
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao J, Perlman S. Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-γ, IL-2 and IL-2R. PLoS One 2012; 7:e46241; PMID:23029447; https://doi.org/10.1371/journal.pone.0046241
   PubMed Web of Science ®Google Scholar
• Belz GT. ILC2s masquerade as ILC1s to drive chronic disease. Nat Immunol 2016; 17:611-2; PMID:27196511; https://doi.org/10.1038/ni.3467
   PubMed Web of Science ®Google Scholar
• Trabanelli S, La Manna F, Romano M, Salvestrini V, Cavo M, Ciciarello M, Lemoli RM, Curti A. The human mesenchymal stromal cell-derived osteocyte capacity to modulate dendritic cell functions is strictly dependent on the culture system. J Immunol Res 2015; 2015:526195; PMID:26247040; https://doi.org/10.1155/2015/526195
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29:392-7; PMID:21149668; https://doi.org/10.1200/JCO.2010.32.2446
   PubMed Web of Science ®Google Scholar